Clinical Trials Logo

E-cigarettes clinical trials

View clinical trials related to E-cigarettes.

Filter by:
  • None
  • Page 1

NCT ID: NCT04053868 Completed - Tobacco Smoking Clinical Trials

Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

This is an observational, crossover design that will examine the pharmacokinetics and pharmacodynamics of impact of smoking tobacco cigarettes or vaping the JUUL electronic cigarette.

NCT ID: NCT03153228 Enrolling by invitation - E-cigarettes Clinical Trials

Acute Response to Cigarette and E-cigarette Smoking Assesed in Exhaled Breath Condensate in Healthy Smokers of Traditional and E-cigarettes

Start date: May 8, 2017
Phase: N/A
Study type: Observational

Electronical cigarettes, also known as "e-cigarettes" are a new phenomenon, which steadily wins more aprobation among smokers. However, there exists no much data concerning the effects of acute exposure to electronic cigarettes vapour on the respiratory system. The aim of the present study is to evaluate and compare the acute response to electronic and traditional cigarettes in healthy smokers.

NCT ID: NCT02783768 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

VaPE-Tox
Start date: March 1, 2017
Phase: Early Phase 1
Study type: Interventional

Determination of the acute pulmonary toxicities of e-cigarettes in young adults is of major public health importance, as e-cigarette vapor contains established toxicants that as hypothesized cause acute damage to the airways and the pulmonary microvasculature that may promote the development of CLD, for which there remain few effective therapies. The study therefore propose a pilot study using a randomized crossover design in ten healthy young adults to test the acute effects of a standardized e-cigarette exposure on two sensitive, safe, non-invasive imaging measures: (1) ventilation defects on hyperpolarized helium-enhanced magnetic resonance imaging, and (2) pulmonary microvascular blood flow on gadolinium-enhanced pulmonary magnetic resonance angiography.